Icon
+91 94997 68112
Login Register

Tivicay - (10, 25, 50 mg; Tablet, Oral)

Dolutegravir Sodium VIIV Healthcare
10, 25, 50 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
More Than 5
More Than 5
More Than 5
None None
Indicated in combination with: other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 30 kg
Yes
*****, ******, *****, *****, ** *****'*, ****** *** *** ***** ** **** **** ** **** ****** '***(*** *, ****) *** **** ************ *********. ** ****** **** **** ***** ********* ****** ** *** ****. ** ** ********* ** **** **** ***** ** *** **** ****** ********** *** **** *.*. ****** '***(*** *, ****) *** **** ** *** ********* *** ********* *** **** ******. ******** ****** ** ************ ****** ** *** ****. *** ********* ** **** ****** (** *****'*) *** *********** ** ****** **** ** *** ****. ******* ********** **** **** **** *** ******* ****** **** ******* ** ** *****'*. ****** *** ********* ******** *** ******* **** **** **********. ***** **** *** ***** ******* ********** ** *** *, ****. **** ********** ******* **** ****** *** ******.
Tivicay Patent 1 Patent 2
***** *** ********* *******
****** *** ********* *******
***** *** ********* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ** *** **, **** ******* **** ***** *** **** ***********
****** *** \ ** *** **, **** ******* **** ***** *** **** ***********
***** *** \ *** *** **, **** ******* ********* ******** ***** *** **** (***** ******)
  1. *** **, **** : *****, ******, *****, *****, ** *****'* ******** ******** ***** ***** **** ** **** ****** '***(*** *, ****).
  2. *** **, **** : ******** ***** * **** ******* *****, ******, *****, *****, ** *****'*.
  3. *** **, **** : ****** ******** ******** ***** *** **** ** **** ****** '***(*** *, ****).
  4. *** **, **** : ******** ***** * **** ******* ******.
  5. *** **, **** : ********** ********* **** ** *****'*
  6. *** **, **** : *****://***.**********.***.***/**********_****/*********/****/********************.*** ********* ******** ** ****** ****
  7. *** *, **** : **** ********** ******* **** ****** (** *****).
  8. *** *, **** : **** ********** ******* **** *****.
  9. *** **, **** : **** ********** ******* **** ****** **** ******* *****.
  10. *** *, **** : **** ********** ******* **** ****** **** ******* *****.
  11. *** *, **** : **** ********** ******* **** ******.
  12. *** **, **** : ****** ******** **** ********** ***** *** **** ** ******.
  13. *** *, **** : **** ********** ******* **** ******.
  14. *** *, **** : **** ********** **** ****** **** ************ ** ****** ** '***.
  15. *** *, **** : **** ********** ******* **** ******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.